Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4
Abstract
Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All patients received treatment with NUC for at least 18 months. Patients with CHB or compensated cirrhosis were included. Patients with HCC diagnosed before or during the first 18 months of NUC therapy were excluded. Results. HCC was diagnosed in 2 CHB patients (1.0%) and 23 cirrhosis patients (20%) (OR = 24.41, 95% CI 5.40 < OR < 153.2; p < 0.0001). Multivariate analysis revealed that HCC risk was independently associated with age ≥ 60 years (OR = 6.45, 95% CI 1.22 to 34.0; p = 0.02) and liver cirrhosis (OR = 12.1, 95% CI 1.39 to 106.2; p = 0.02), but not with virological response (VR), and previous resistance to NUC, or rescue therapy. Multivariate analysis in cirrhosis patients revealed that only age ≥ 60 years was an independent risk factor associated with HCC (p = 0.003). Conclusions. Liver cirrhosis and age ≥ 60 years are the stronger risk factors for HCC in genotype D HBeAgnegative patients. Previous resistance to NUC in patients that achieved a VR after rescue therapy was not a predictive factor regarding HCC. VR does not appear to significantly reduce the overall incidence of HCC when a patient has already progressed to liver cirrhosis.
Authors and Affiliations
Adriano M. Pellicelli, Pascal Vignally, Vincenzo Messina, Antonio Izzi, Ettore Mazzoni, Angelo Barlattani, Donato Bacca, Mario Romano, Fabrizio Mecenate, Tommaso Stroffolini, Caterina Furlan, Umberto V. Gentilucci, Roberto Gulminetti, Maria E. Bonaventura, Cecilia D’Ambrosio, Amerigo Paffetti, Cristina Mastropietro, Massimo Marignani, Lucia Fondacaro, Giuseppe Cerasari, Arnaldo Andreoli, Giorgio Barbarini
Keywords
Related Articles
- EP ID EP78415
- DOI -
- Views 129
- Downloads 0
Tenofovir-induced Fanconi syndrome in a patient with chronic hepatitis B monoinfection
Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor indicated for treatment of patients with chronic hepatitis B virus (CHB) and human immunodeficiency virus (HIV) infections. Despite the...
Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report
Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed s...
Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B
Background and aims. CD4+ T cells play an important role in response to hepatitis B virus (HBV) infection. We investigated thechange in CD4+ T-cell subpopulations and viral load in patients with chronic HBV infection wh...
A New Stage in Annals of Hepatology
-<br/><br/>
Graft calcification caused by a torsion of the hepatic vein after a living-related donor liver transplantation
The torsion of vessels after liver transplantation rarely occurs. Likewise, calcification of a liver graft has seldom been reported. This report details a case which had torsion of the left hepatic vein on the seventh d...